Associations between prenatal malaria exposure, maternal antibodies at birth, and malaria susceptibility during the first year of life in Burkina Faso
Hamtandi Magloire Natama(Centre National de la Recherche Scientifique et Technologique), Carlota Dobaño(Manhiça Health Research Centre), Marta Vidal(Barcelona Institute for Global Health), Ross L. Coppel(Australian Regenerative Medicine Institute), Halidou Tinto(Institut de Recherche en Sciences de la Santé), Chetan E. Chitnis(Institut Pasteur), D. Cavanagh(Organic Research Centre), Alfons Jiménez(Barcelona Institute for Global Health), Gemma Moncunill(Barcelona Institute for Global Health), Luís Izquierdo(Barcelona Institute for Global Health), Rebeca Santano(Centro de Investigación en Red en Enfermedades Cardiovasculares), Ruth Aguilar(Barcelona Institute for Global Health), Henk D. F. H. Schallig(Amsterdam University Medical Centers), Pètra F. Mens(Amsterdam UMC Location University of Amsterdam), James G. Beeson(Burnet Institute), Benoît Gamain(Inserm), Anna Rosanas‐Urgell(Instituut voor Tropische Geneeskunde), Evelina Angov(Walter Reed Army Institute of Research), Hermann Sorgho(Institut de Recherche en Sciences de la Santé), Toussaint Rouamba(Institut de Recherche en Sciences de la Santé), Eduard Rovira-Vallbona(Instituut voor Tropische Geneeskunde), Maminata Coulibaly-Traoré(Institut de Recherche en Sciences de la Santé), Innocent Valéa(Institut de Recherche en Sciences de la Santé), M. Athanase Somé(Institut de Recherche en Sciences de la Santé), Sheetij Dutta(Walter Reed Army Institute of Research)
Cited by 12
Related Papers
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
|The Lancet|2021|457
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
|New England Journal of Medicine|2015|451
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
|The Lancet|2024|345
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial
|The Lancet Infectious Diseases|2022|285
Novel serologic biomarkers provide accurate estimates of recent <i>Plasmodium falciparum</i> exposure for individuals and communities
|Proceedings of the National Academy of Sciences|2015|219